# US 2018/0020669 A1 · Methods for the Inhibition and Dispersal of Biofilms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0020669 A1
- Document ID: US20180020669A1
- Status: Published application
- Kind: A1
- Application number: 15/549,369
- Filed: 2016-02-04
- Published: 2018-01-25
- Earliest claimed: 2015-02-06
- Assignees: Auspherix Limited
- Applicants: Auspherix Limited
- Inventors: Ian Charles; Alber Dagmar
- Web page: https://patentgrep.com/patent/US20180020669A1

## CPC

- A01N 59/16: Heavy metals; Compounds thereof
- A01N 43/16: with oxygen as the ring hetero atom
- A01N 43/60: 1,4-Diazines; Hydrogenated 1,4-diazines
- A01N 43/90: having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A01N 57/18: having phosphorus-to-carbon bonds (A01N57/02 takes precedence)
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/7135: Compounds containing heavy metals
- A61K 33/242: Gold; Compounds thereof
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods for inhibiting microbial growth, inhibiting biofilm formation or development, disrupting existing biofilms, reducing the biomass of a biofilm, and methods for sensitizing a biofilm and microorganisms with the biofilm to an antimicrobial agent.

## Claims

### Claim 1

A method for reducing the biomass of a biofilm in a subject in need thereof, comprising exposing the biofilm to an effective amount of auranofin.

### Claim 2

A method for promoting the dispersal of microorganisms from a biofilm in a subject in need thereof, comprising exposing the biofilm to an effective amount of auranofin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the biofilm comprises bacteria.

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The method of claim 2, wherein the biofilm comprises at least one of: Gram positive bacteria, bacteria having a thioredoxin (Trx) pathway, bacteria that do not have a glutathione (GSH) and glutathione reductase pathway (GR), and/or bacteria that do not express γ-glutamate-cysteine ligase (GshA), glutathione synthetase (GshB), or glutathione reductase (Gor).

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 2)

The method of claim 2, wherein the biofilm comprises at least one of: multi-drug resistant bacteria, S. aureus, methicillin-resistant S. aureus (MRSA), A. baumannii, K. pneumoniae, fungi, C. albicans, or C. neoformans.

### Claim at position 8

9-21. (canceled)

### Claim 22 (depends on 2)

The method of claim 2, wherein the biofilm is a single species biofilm or a mixed species biofilm.

### Claim 23

A method for inhibiting biofilm formation in a subject in need thereof, comprising exposing a biofilm-forming microorganism in said subject to an effective amount of auranofin.

### Claim 24 (depends on 23)

The method of claim 23, wherein the biofilm-forming microorganism is at least one of a bacterium, a Gram positive bacterium, a bacterium having a thioredoxin (Trx) pathway, a bacterium that does not have a glutathione (GSH) and glutathione reductase pathway (GR), a bacterium that does not have a glutathione (GSH) and glutathione reductase pathway (GR), a multi-drug resistant bacterium, S. aureus, MRSA, A. baumannii, K. pneumoniae, a fungus, C. albicans, or C. neoformans.

### Claim at position 12

25-36. (canceled)

### Claim 37 (depends on 23)

The method of claim 23, wherein the auranofin is coated, impregnated or otherwise contacted with a surface or interface susceptible to biofilm formation.

### Claim 38 (depends on 37)

The method of claim 37, wherein the surface is a surface of medical or surgical equipment, an implantable medical device or prosthesis.

### Claim 39 (depends on 2)

The method of claim 2, wherein the biofilm or biofilm-forming microorganism is on a bodily surface of a subject and exposure of the biofilm or biofilm-forming microorganism to auranofin is by administration of the auranofin to the subject.

### Claim 40 (depends on 39)

The method of claim 39, wherein the biofilm or biofilm-forming microorganism is associated with an infection, disease or disorder suffered by the subject or to which the subject is susceptible.

### Claim 41 (depends on 2)

The method of claim 2, further comprising exposing the biofilm or biofilm-forming microorganism to at least one additional antimicrobial agent.

### Claim 42 (depends on 41)

The method of claim 41, wherein the additional antimicrobial agent is an antibiotic or an anti-fungal agent.

### Claim 43 (depends on 42)

The method of claim 42, wherein the antibiotic is selected from rifampicin, gentamicin, erythromycin, lincomycin and vancomycin.

### Claim 44

A method of sensitizing a microorganism in a biofilm to an antimicrobial agent by exposing the biofilm to an effective amount of auranofin.

### Claim 45 (depends on 44)

The method of claim 44, wherein the microorganism is at least one of a bacterium, a Gram positive bacterium, a bacterium having a thioredoxin (Trx) pathway, a bacterium that does not have a glutathione (GSH) and glutathione reductase pathway (GR), a bacterium that does not express γ-glutamate-cysteine ligase (GshA), glutathione synthetase (GshB), and/or glutathione reductase (Gor), a multi-drug resistant bacterium, S. aureus, MRSA, A. baumannii, K. pneumoniae, a fungus, C. albicans, or C. neoformans.

### Claim at position 22

46-57. (canceled)

### Claim 58 (depends on 44)

The method of claim 44, wherein the antimicrobial agent is an antibiotic or an antifungal agent.

### Claim 59 (depends on 58)

The method of claim 58, wherein the antibiotic is selected from rifampicin, gentamicin, erythromycin, lincomycin and vancomycin.

### Claim at position 25

60-63. (canceled)

### Claim 64 (depends on 1)

The method of claim 1, wherein the biofilm comprises at least one of: Gram positive bacteria, multi-drug resistant bacteria, S. aureus, methicillin-resistant S. aureus (MRSA), A. baumannii, K. pneumoniae, a fungi, C. albicans, or C. neoformans.

### Claim 65 (depends on 1)

The method of claim 1, wherein the biofilm or biofilm-forming microorganism is on a bodily surface of a subject and exposure of the biofilm or biofilm-forming microorganism to auranofin is by administration of the auranofin to the subject.

### Claim 66 (depends on 65)

The method of claim 65, wherein the biofilm or biofilm-forming microorganism is associated with an infection, disease or disorder suffered by the subject or to which the subject is susceptible.

### Claim 67 (depends on 1)

The method of claim 1, further comprising exposing the biofilm or biofilm-forming microorganism to at least one additional antimicrobial agent.

### Claim 68 (depends on 67)

The method of claim 67, wherein the additional antimicrobial agent is an antibiotic or an anti-fungal agent.

### Claim 69 (depends on 68)

The method of claim 68, wherein the antibiotic is selected from rifampicin, gentamicin, erythromycin, lincomycin and vancomycin.
